Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Glaucoma · Macular Edema

Allergan Pharmaceuticals International

Allergan Pharmaceuticals International Limited

Allergan Pharmaceuticals International clinical programs — 13 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Dublin, IE HQ
EMA registrant Type
Company details
Status
Public
HQ
Dublin, IE
Programs
13
Drugs
15
Patents
25
All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Allergan Pharmaceuticals International projects

13 ClinicalTrials.gov programs sponsored by Allergan Pharmaceuticals International.

Allergan Pharmaceuticals International has 13 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

13 programs

Clinical programs

  1. 700 µg Dexamethasone

    Allergan Pharmaceuticals International Limited

    Macular Edema

    phase 3 small molecule completed

    1 trial

  2. AGN-195263

    Allergan Pharmaceuticals International Limited

    Dry Eye Syndromes

    phase 3 small molecule terminated

    1 trial

  3. Abicipar Pegol

    Allergan Pharmaceuticals International Limited

    Macular Degeneration

    phase 3 small molecule completed

    1 trial

  4. Placebo

    Allergan Pharmaceuticals International Limited

    Gastroparesis

    phase 3 small molecule terminated

    3 trials

  5. Rapastinel

    Allergan Pharmaceuticals International Limited

    Depressive Disorder, Major

    phase 3 small molecule terminated

    1 trial

  6. XEN45

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 other completed

    1 trial

  7. bimatoprost ophthalmic solution formulation A

    Allergan Pharmaceuticals International Limited

    Glaucoma

    phase 3 small molecule terminated

    1 trial

  8. botulinum toxin Type A

    Allergan Pharmaceuticals International Limited

    Pediatrics

    phase 3 mab completed

    4 trials

  9. AGN 211745

    Allergan Pharmaceuticals International Limited

    Choroid Neovascularization

    phase 2 small molecule terminated

    1 trial

  10. Brimo PS DDS®

    Allergan Pharmaceuticals International Limited

    Patients Who Participated in an Intravitreal Brimo PS DDS® Study

    phase 2 small molecule completed

    1 trial

  11. Gatifloxacin 0.3% ophthalmic solution

    Allergan Pharmaceuticals International Limited

    Acute Bacterial Corneal Ulcers

    phase 2 small molecule completed

    1 trial

  12. botulinum toxin Type A

    Allergan Pharmaceuticals International Limited

    Benign Prostatic Hyperplasia

    phase 2 mab completed

    1 trial

  13. botulinum toxin type A

    Allergan Pharmaceuticals International Limited

    Cervical Dystonia

    phase 2 mab completed

    1 trial

Frequently asked questions

How many clinical projects does Allergan Pharmaceuticals International have?

13 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.